Literature DB >> 17128693

The effect of physician-patient discussions on the likelihood of prostate-specific antigen testing.

Louie E Ross1, Lisa C Richardson, Zahava Berkowitz.   

Abstract

Many medical and professional organizations agree that men should discuss the advantages and disadvantages of testing for prostate-specific antigen (PSA) with their physicians before undergoing testing. In the 2000 National Health Interview Survey, men who had undergone a PSA test in the past were asked about their use of this test and discussions they had with physicians regarding its advantages and disadvantages. Among a group of 2,188 black and white men aged 40-79 years with no history of prostate cancer and a history of testing for PSA, we examined whether physician-patient discussions mediated the relationship between race and PSA testing. We specified that the test had to be their most recent one and part of a routine physical examination or screening test. We compared those tested within the past two years with those tested >2 years. Almost two-thirds of the men previously had discussions with their physicians about the advantages and disadvantages of the PSA test. Older men, college graduates, those living in the midwest and those with health insurance were more likely to have been tested recently. Discussion with a physician was found to mediate the relationship between race and PSA testing during the past two years. Black men were initially found to be more likely than white men to have been screened recently [odds ratio (OR)=1.45; 95% confidence interval (CI) 1.01-2.07], but in the full model race was no longer significant (OR=1.41; 95% Cl 0.98-2.03). Discussions about PSA testing were associated with more recent PSA screening (OR=1.38, 95% CI 1.05-1.82). These findings suggest that: 1) the relationships among race, physician discussions and PSA testing may need to be examined in more complex ways, and 2) the physician has an important role in men's decision to consider PSA testing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17128693      PMCID: PMC2569778     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  19 in total

1.  Prostate cancer as a public health issue in North Carolina.

Authors:  N Stark; E Paskett; W Demark-Wahnefried; E Carbone; P Godley
Journal:  N C Med J       Date:  2001 Sep-Oct

2.  Screening for prostate cancer: recommendation and rationale.

Authors: 
Journal:  Ann Intern Med       Date:  2002-12-03       Impact factor: 25.391

3.  Knowledge, attitudes, and screening practices among older men regarding prostate cancer.

Authors:  C B Steele; D S Miller; C Maylahn; R J Uhler; C T Baker
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

4.  Sociodemographic and health status characteristics with prostate cancer screening in a national cohort of middle-aged male veterans.

Authors:  S A Eisen; B Waterman; C S Skinner; J F Scherrer; J C Romeis; K Bucholz; A Heath; J Goldberg; M J Lyons; M T Tsuang; W R True
Journal:  Urology       Date:  1999-03       Impact factor: 2.649

5.  Prostate cancer screening in primary care.

Authors:  F Carter; E Graham; N Pal; E Gonzalez; R Roetzheim
Journal:  South Med J       Date:  1999-03       Impact factor: 0.954

6.  The validity of male patients' self-reports regarding prostate cancer screening.

Authors:  T R Jordan; J H Price; K A King; T Masyk; A W Bedell
Journal:  Prev Med       Date:  1999-03       Impact factor: 4.018

7.  Physician-patient discussions of controversial cancer screening tests.

Authors:  A S Dunn; K V Shridharani; W Lou; J Bernstein; C R Horowitz
Journal:  Am J Prev Med       Date:  2001-02       Impact factor: 5.043

8.  Concordance of self-reported data and medical record audit for six cancer screening procedures.

Authors:  N P Gordon; R A Hiatt; D I Lampert
Journal:  J Natl Cancer Inst       Date:  1993-04-07       Impact factor: 13.506

9.  Relation of family history of prostate cancer to perceived vulnerability and screening behavior.

Authors:  Paul B Jacobsen; Laurie A Lamonde; Melissa Honour; Kathryn Kash; Perry B Hudson; Julio Pow-Sang
Journal:  Psychooncology       Date:  2004-02       Impact factor: 3.894

10.  Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening.

Authors:  W Demark-Wahnefried; T Strigo; K Catoe; M Conaway; M Brunetti; B K Rimer; C N Robertson
Journal:  Urology       Date:  1995-09       Impact factor: 2.649

View more
  6 in total

1.  Measuring Preferences for Colorectal Cancer Screening: What are the Implications for Moving Forward?

Authors:  Deborah Marshall; S Elizabeth McGregor; Gillian Currie
Journal:  Patient       Date:  2010-06-01       Impact factor: 3.883

2.  Low-level arsenic exposure from drinking water is associated with prostate cancer in Iowa.

Authors:  Taehyun Roh; Charles F Lynch; Peter Weyer; Kai Wang; Kevin M Kelly; Gabriele Ludewig
Journal:  Environ Res       Date:  2017-09-18       Impact factor: 6.498

3.  Shared decision making in prostate-specific antigen testing with men older than 70 years.

Authors:  Jun Li; Zahava Berkowitz; Thomas B Richards; Lisa C Richardson
Journal:  J Am Board Fam Med       Date:  2013 Jul-Aug       Impact factor: 2.657

4.  Decision-making processes for breast, colorectal, and prostate cancer screening: the DECISIONS survey.

Authors:  Richard M Hoffman; Carmen L Lewis; Michael P Pignone; Mick P Couper; Michael J Barry; Joann G Elmore; Carrie A Levin; John Van Hoewyk; Brian J Zikmund-Fisher
Journal:  Med Decis Making       Date:  2010 Sep-Oct       Impact factor: 2.583

5.  Men's knowledge and beliefs about prostate cancer: education, race, and screening status.

Authors:  Julie A Winterich; Joseph G Grzywacz; Sara A Quandt; Peter E Clark; David P Miller; Joshua Acuña; Mark B Dignan; Thomas A Arcury
Journal:  Ethn Dis       Date:  2009       Impact factor: 1.847

6.  How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey.

Authors:  Deborah A Marshall; F Reed Johnson; Nathalie A Kulin; Semra Ozdemir; Judith M E Walsh; John K Marshall; Stephanie Van Bebber; Kathryn A Phillips
Journal:  Health Econ       Date:  2009-12       Impact factor: 3.046

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.